Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Xspray Pharma in connection with its rights issue of units
Mandate

Vinge is advising Xspray Pharma in connection with its rights issue of units

May 04, 2023 Capital Markets and Public M&A

Through the rights issue of units, Xspray is expected to receive approximately SEK 300 million, with two warrant series approximately amounting together up to an additional SEK 300 million upon full exercise.

Xspray Pharma AB (publ) is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment. The company's goal is to become a leader in the development of improved PKIs for cancer treatment. Xspray’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Linnéa Sellström and Adrian Filipovic.

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025